SUMOylation Pattern Predicts Prognosis and Indicates Tumor Microenvironment Infiltration Characterization in Bladder Cancer

被引:19
作者
Xia, Qi-Dong [1 ]
Sun, Jian-Xuan [1 ]
Xun, Yang [1 ]
Xiao, Jun [1 ]
Liu, Chen-Qian [1 ]
Xu, Jin-Zhou [1 ]
An, Ye [1 ]
Xu, Meng-Yao [1 ]
Liu, Zheng [1 ]
Wang, Shao-Gang [1 ]
Hu, Jia [1 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept & Inst Urol, Wuhan, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
基金
中国国家自然科学基金;
关键词
SUMOylation; tumor microenvironment; tumor mutation burden; bladder cancer; immunotherapy; MEDIATED REGULATION; OPEN-LABEL; EXPRESSION; MULTICENTER; MONOTHERAPY; PROGRESSION; CARCINOMA; RISK; UBC9;
D O I
10.3389/fimmu.2022.864156
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
BackgroundSUMOylation is an important component of post-translational protein modifications (PTMs), and bladder cancer (BCa) is the ninth most common cancer around the world. But the comprehensive role of SUMOylation in shaping tumor microenvironment (TME) and influencing tumor clinicopathological features and also the prognosis of patients remains unclear. MethodsUsing the data downloaded from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO), we comprehensively evaluated the SUMOylation patterns of 570 bladder cancer samples, and systematically correlated these SUMOylation patterns with TME immune cell infiltrating characteristics. The SUMO score was constructed to quantify SUMOylation patterns of individuals using principal component analysis (PCA) algorithms. ResultsTwo distinct SUMOylation patterns and gene clusters were finally determined. Significant differences in the prognosis of patients were found among two different SUMOylation patterns and gene clusters, so were in the mRNA transcriptome and the landscape of TME immune cell infiltration. We also established a set of scoring system named SUMO score to quantify the SUMOylation pattern of individuals with BCa, which was discovered to be tightly connected with tumor clinicopathological characteristics and could predict the prognosis of patients with BCa. Moreover, SUMO score was a considerable predictive indicator for the survival outcome independent of tumor mutation burden (TMB) and low SUMO score was related to better response to immunotherapy using PD-1 blockade. We also found that there existed a significant relationship between sensitivity to commonly used chemotherapy drugs and SUMO score. Finally, a nomograph based on five features, namely, SUMO score, age, gender, T category, and M category was constructed to predict the survival probability of patients with BCa in 1, 3, and 5 years, respectively. ConclusionsOur work demonstrated and overviewed the complicated regulation mechanisms of SUMOylation in bladder cancer, and better understanding and evaluating SUMOylation patterns could be helpful in guiding clinical therapeutic strategy and improving the prognosis of patients with BCa.
引用
收藏
页数:18
相关论文
共 56 条
  • [1] Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends
    Antoni, Sebastien
    Ferlay, Jacques
    Soerjomataram, Isabelle
    Znaor, Ariana
    Jemal, Ahmedin
    Bray, Freddie
    [J]. EUROPEAN UROLOGY, 2017, 71 (01) : 96 - 108
  • [2] European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-2019 Update
    Babjuk, Marko
    Burger, Maximilian
    Comperat, Eva M.
    Gontero, Paolo
    Mostafid, A. Hugh
    Palou, Joan
    van Rhijn, Bas W. G.
    Roupret, Morgan
    Shariat, Shahrokh F.
    Sylvester, Richard
    Zigeuner, Richard
    Capoun, Otakar
    Cohen, Daniel
    Dominguez Escrig, Jose Luis
    Hernandez, Virginia
    Peyronnet, Benoit
    Seisen, Thomas
    Soukup, Viktor
    [J]. EUROPEAN UROLOGY, 2019, 76 (05) : 639 - 657
  • [3] Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
    Balar, Arjun, V
    Kamat, Ashish M.
    Kulkarni, Girish S.
    Uchio, Edward M.
    Boormans, Joost L.
    Roumiguie, Mathieu
    Krieger, Laurence E. M.
    Singer, Eric A.
    Bajorin, Dean F.
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuki
    Konety, Badrinath R.
    Li, Haojie
    Nam, Kijoeng
    Kapadia, Ekta
    Frenkl, Tara
    de Wit, Ronald
    [J]. LANCET ONCOLOGY, 2021, 22 (07) : 919 - 930
  • [4] PPAR-γ Agonists and Their Effects on IGF-I Receptor Signaling: Implications for Cancer
    Belfiore, A.
    Genua, M.
    Malaguarnera, R.
    [J]. PPAR RESEARCH, 2009, 2009
  • [5] Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy
    Bellmunt, J.
    Paz-Ares, L.
    Cuello, M.
    Cecere, F. L.
    Albiol, S.
    Guillem, V.
    Gallardo, E.
    Carles, J.
    Mendez, P.
    de la Cruz, J. J.
    Taron, M.
    Rosell, R.
    Baselga, J.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 (03) : 522 - 528
  • [6] Understanding the tumor immune microenvironment (TIME) for effective therapy
    Binnewies, Mikhail
    Roberts, Edward W.
    Kersten, Kelly
    Chan, Vincent
    Fearon, Douglas F.
    Merad, Miriam
    Coussens, Lisa M.
    Gabrilovich, Dmitry I.
    Ostrand-Rosenberg, Suzanne
    Hedrick, Catherine C.
    Vonderheide, Robert H.
    Pittet, Mikael J.
    Jain, Rakesh K.
    Zou, Weiping
    Howcroft, T. Kevin
    Woodhouse, Elisa C.
    Weinberg, Robert A.
    Krummel, Matthew F.
    [J]. NATURE MEDICINE, 2018, 24 (05) : 541 - 550
  • [7] Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
    Chan, T. A.
    Yarchoan, M.
    Jaffee, E.
    Swanton, C.
    Quezada, S. A.
    Stenzinger, A.
    Peters, S.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (01) : 44 - 56
  • [8] Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade
    Charoentong, Pornpimol
    Finotello, Francesca
    Angelova, Mihaela
    Mayer, Clemens
    Efremova, Mirjana
    Rieder, Dietmar
    Hackl, Hubert
    Trajanoski, Zlatko
    [J]. CELL REPORTS, 2017, 18 (01): : 248 - 262
  • [9] SUMOylation promotes extracellular vesicle-mediated transmission of lncRNA ELNAT1 and lymph node metastasis in bladder cancer
    Chen, Changhao
    Zheng, Hanhao
    Luo, Yuming
    Kong, Yao
    An, Mingjie
    Li, Yuting
    He, Wang
    Gao, Bowen
    Zhao, Yue
    Huang, Hao
    Huang, Jian
    Lin, Tianxin
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2021, 131 (08)
  • [10] Elements of cancer immunity and the cancer-immune set point
    Chen, Daniel S.
    Mellman, Ira
    [J]. NATURE, 2017, 541 (7637) : 321 - 330